slides · global inventory
27 Cost Of Inaction
Loop collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 31,900
Current window 17,971-18,000
Pages 1,064
Rows per page 30
Loop
17,971-18,000 of 31,900
03
The slide uses a three-column structure to summarize the company's value proposition.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
The slide uses a Gantt-style chart to show clinical trial progress for multiple assets.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
The slide uses a Gantt-style timeline to track clinical trial progress (P2 data, enrollment, FPI) against calendar years.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
The chart uses a dual-line comparison to show the divergence in risk outcomes based on treatment timing.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
07
Includes box plot showing 10th/90th percentiles and line chart showing concentration over 20 minutes.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
08
Box plot showing baseline adjusted epinephrine Tmax.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
09
Shows rapid onset of therapeutic benefits for AQST-109.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
10
Clinical trial data comparing sublingual/oral film (AQST-109) vs intramuscular injection.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
04
The slide uses academic citations to establish the clinical relevance of the target protein.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
05
Includes a scientific diagram of the signaling pathway and references to academic literature.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
Includes a bifurcation diagram illustrating the relationship between SNAIL and ZEB mRNA levels in different cell phenotypes.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
11
Uses a split-layout: left side provides market context/sizing, right side provides clinical pain points.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
12
The slide uses a line chart to demonstrate clinical efficacy over 12 weeks compared to baseline.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
06
The slide uses a three-column structure to frame the problem: Market State, Biological Complexity, and Clinical Need.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Beat · Problem StatementLoop · Cost Of Inaction1 hit
07
The slide uses a timeline framework to show trial progression over time.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
08
Axcella Health | Results Presentation Deck | 62 slidesAxcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Beat · Key TakeawaysLoop · Cost Of Inaction1 hit
09
The slide uses a blue box with checkmarks to emphasize the positive attributes of the product.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
10
Axcella Health | Results Presentation Deck | 62 slidesAxcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
11
The slide uses a standard clinical trial flow diagram to illustrate study arms and assessment points.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
12
Standard clinical trial subject disposition flow chart.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
13
The table includes demographic, metabolic, inflammatory, and fibrosis markers.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
14
Axcella Health | Results Presentation Deck | 62 slidesAxcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
15
The data shows a statistically significant improvement in the high-dose group at Week 24.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Cost Of Inaction1 hit
16
The slide shows clinical trial data comparing two biomarkers for fibrosis treatment efficacy.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
17
Clinical trial data showing statistically significant reductions in ALT for AXA1125 groups compared to placebo.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
18
Shows statistically significant effects at week 12 for AXA1125 treatment arms.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
19
Data shows proportions of subjects meeting specific thresholds associated with histologic improvements in NASH.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
20
Axcella Health | Results Presentation Deck | 62 slidesAxcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
21
DMC = Data Monitoring Committee; TEAE = Treatment Emergent Adverse Event; SAE = Serious Adverse Event.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit